Clinical trials: Hepatic Malignancies
Hepatocellular Carcinoma
Pharmacological Manipulation of Intrahepatic Arterial Blood Flow in HCC
Dr Rajan is investigating a new method to improve local treatment of liver cancer. There is evidence that a drug, norepinephrine (NE), has the ability to shrink down normal liver blood vessels, but leave tumor vessels wide open.
- Trial name
- NCT02472249
- Testing
- CT perfusion, Norepinephrine intra-arteriel/hepatic
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- University Health Network, Toronto
Carcinoma, Hepatocellular
GIDEON Non-Nexavar Arm - HCC Patients Who Are Treated With Any Therapy Other Than Nexavar at Individual Study Start
This study is an international prospective, open-label, multi-center, non-interventional study. The protocol will allow enrollment of all patients with diagnosis of HCC in whom a decision to treat with sorafenib has not been made…
- Trial name
- NCT01191385
- Testing
- Any treatment for unresectable HCC as chosen by the physician
- Where
- 24 sites in United States
- Sponsor
- Bayer
Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc)
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
Background: One way to treat liver cancer is to deliver chemotherapy drugs only to the liver (and not to the whole body). Researchers want to see if adding the drug PDS01ADC can improve the treatment.
- Conditions
- Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc), Intrahepatic Bile Duct Cancer, Colorectal Neoplasms
- Trial name
- NCT05286814
- Testing
- Dexamethasone, PDS01ADC, Intera 3000 Hepatic Artery Infusion Pump (HAIP)
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Neoplasms, Lymphomas
Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction
Background: Belinostat is an experimental cancer treatment drug that works by helping to turn on genes that limit cell growth and survival of cancer cells. These genes are often switched off in tumors.
- Trial name
- NCT01273155
- Testing
- Belinostat
- Where
- 7 sites in United States
- Volunteers
- 72 people
- Sponsor
- National Cancer Institute (NCI)
Hepatic Impairment (Mild and Moderate, Child-Pugh Class A and B), Hepatic Insufficiency (MeSH ID: D048550)
Pharmacokinetics and Safety of MDR-001 in Mild and Moderate Hepatic Impairment
This is a Phase I, single-center, open-label, parallel-group study. A single oral dose of MDR-001, a GLP-1 receptor agonist, will be administered to participants with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic…
- Trial name
- NCT07550634
- Testing
- MDR-001
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- MindRank AI Ltd
Breast Cancer, Peripheral Neuropathy
Role of Silymarin in Chemotherapy Toxicity and Cognition Improvement in Breast Cancer Patients
Aim of the work This study aims to evaluate the possible beneficial role of silymarin in attenuating both doxorubicin related cardiac and hepatic toxicities and paclitaxel associated peripheral neuropathy and improving cognitive…
- Conditions
- Breast Cancer, Peripheral Neuropathy, Cardiac Toxicities, Hepatic Toxicity
- Trial name
- NCT05595109
- Testing
- Silymarin
- Where
- Egypt
- Volunteers
- 56 people
- Sponsor
- Tanta University
Colorectal Neoplasms
Safety and Efficacy of Targeted Gene Transfer in Colorectal Cancer Metastatic to Liver
This is a Phase I safety study of a gene transfer drug for colorectal cancer that has spread to the liver. The main purpose of this study is to determine if it is safe to give this new intervention to persons with cancer, but we…
- Trial name
- NCT00035919
- Testing
- Mx-dnG1 Retroviral Vector
- Sponsor
- University of Southern California
Resectable Hepatocellular Carcinoma Beyond Milan Criteria
Hepatectomy Versus Chemoembolization for Resectable Hepatocellular Carcinoma Beyond Milan Criteria
The purpose of this study is to compare the survival outcomes between hepatic resection and transarterial lipiodol chemoembolization (TACE) used as the initial treatment in patients with Resectable Hepatocellular Carcinoma Beyond…
- Trial name
- NCT02138981
- Testing
- Chemoembolization and Response-Dependent Resection, Immediate Resection
- Where
- China
- Volunteers
- 436 people
- Sponsor
- Sun Yat-sen University
Liver Cancer (Primary and Metastatic), Liver Ablation
Clinical Study on the Safety, Efficacy, and Exploration of Immune Mechanisms of a Combined Multimodal Tumor Therapy System for Hepatic Malignancies
Clinical Study on the Safety, Efficacy, and Exploration of Immune Mechanisms of a Combined Multimodal Tumor Therapy System for Hepatic Malignancies
- Trial name
- NCT07459309
- Testing
- Multimodal Tumor Thermal Ablation
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fudan University
Colorectal Carcinoma
Utility of PET In the Pre-Operative Assessment of Patients With Hepatic Colorectal Metastases
This study aims to determine whether a test, called the PET scan, may be useful in determining if there are additional locations of cancer not otherwise detectable by other tests.
- Trial name
- NCT00588549
- Where
- United States
- Volunteers
- 204 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Liver Failure
Registry Protocol for Tracking Trial Subjects After VTI-206 Study Completion
VTI-207 (NCT01452295) is designed to follow subjects, both treated and control, for five years after their completion of study participation in protocol VTI-206 (NCT00973817) to gather information relating to the incidence of…
- Trial name
- NCT01452295
- Testing
- ELAD (Extracorporeal Liver Assist System)
- Sponsor
- Vital Therapies, Inc.
Cholangiocarcinoma
Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Tislelizumab and Regorafenib as First-Line Therapy for Advanced Cholangiocarcinoma
The goal of this clinical trial is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) combined with tislelizumab and regorafenib as first-line therapy in patients with locally advanced or…
- Trial name
- NCT07619937
- Testing
- HAIC Combined with Tislelizumab and Regorafenib
- Where
- China
- Volunteers
- 31 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Hepatic Impairment
Pharmacokinetics and Safety Study of Siremadlin (HDM201) in Participants With Mild, Moderate and Severe Hepatic Impairment
The main purpose of this study is to evaluate the effect of varying degrees of impaired hepatic function (by Child Pugh classification) on the plasma PK of siremadlin after a single oral dose.
- Trial name
- NCT05599932
- Testing
- Siremadlin
- Where
- 3 sites in United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Oncologic Surgery, Cancer
Optimal Perioperative Pain Control in Minimally Invasive Abdominal Cancer Surgery
This is a research study to evaluate the effectiveness of 3 different types of routine pain management regimens used during clinically indicated, minimally invasive oncologic (cancer) surgery.
- Conditions
- Oncologic Surgery, Cancer, Cancer Surgery, Hepatic Cancer
- Trial name
- LapTAP (NCT06731998)
- Testing
- Local Anesthesia, Laparoscopic Transversus Abdominis Plane block
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
HCC - Hepatocellular Carcinoma
EDN Combined With TACE/HAIC and Second-Line Immune-Targeted Treatment Versus TACE/HAIC Alone in Locally Advanced HCC With Portal Vein Tumor Thrombosis After First-Line Therapy Failure: A Prospective, Multicenter, Randomized Controlled Trial
The goal of this clinical trial is to evaluate the efficacy and safety of combining endovascular denervation (EDN) with transarterial chemoembolization/ hepatic arterial infusion chemotherapy (TACE/HAIC) plus second-line…
- Trial name
- NCT07187284
- Testing
- EDN combined with TACE/HAIC and Immuno-Targeted Therapy, TACE/HAIC plus Immuno-Targeted Therapy
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Zhongda Hospital
Pancreatic Neoplasms, Neoplasm Metastasis
Hepatic Resection for Metastatic Pancreatic Cancer
The purpose of this study is to demonstrate the feasibility of an aggressive multimodal approach among patients with stage IV pancreatic cancer (PAC) with isolated, low-volume hepatic metastasis (LVHM).
- Conditions
- Pancreatic Neoplasms, Neoplasm Metastasis, Liver Metastases
- Trial name
- NCT02892305
- Testing
- Hepatic Resection or Ablation with Pancreaticoduodenectomy
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Duke University
Malignant Melanoma
Pharmacokinetic Study of Liposomal Vincristine in Patients With Malignant Melanoma & Hepatic Dysfunction
The purpose of this study is to see how vincristine, when placed in an oil droplet called a liposome (VSLI), is absorbed, distributed (moved around) and excreted from the the body (pharmacokinetics).
- Trial name
- NCT00145041
- Testing
- Vincristine Sulfate Liposomes Injection
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Acrotech Biopharma Inc.
Hepato Cellular Carcinoma (HCC), Hepatobiliary Cancers
Effect and Mechanism of ALPPS Operation on Liver Regeneration
Hepatobiliary malignancies-principally hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA)-are highly aggressive and often diagnosed at advanced stages.
- Conditions
- Hepato Cellular Carcinoma (HCC), Hepatobiliary Cancers, Liver Cancer, Liver Regeneration
- Trial name
- NCT07142213
- Testing
- ALPPS
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Haitao Zhao, MD
Liver Cirrhosis, Hepatic Cell Carcinoma
Value of [68Ga]Ga-PSMA-11 PET/MRI in the Assessment of Liver Cirrhosis
A total of fifty-five (55) patients with liver cirrhosis will be enrolled in this study to produce and validate dedicated Ga-PSMA-PET/MRI acquisition protocols.
- Conditions
- Liver Cirrhosis, Hepatic Cell Carcinoma, Portal Hypertension
- Trial name
- NCT06265272
- Testing
- Injection of a gadolinium contrast agen, Radiotracer Injection, Imaging
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Massachusetts General Hospital
Colorectal Cancer, Metastatic Cancer
Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- ERBIFORT (NCT00557102)
- Testing
- cetuximab, filgrastim, fluorouracil
- Where
- France
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute, France
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.